GLIS2 and cancer: The goal of the present study was not to test the feasibility of using the NKL-derived EVs for directly treating cancers; instead, it aimed to find any novel anticancer effectors of the NKL-derived EVs, as the identification of such effectors could make it possible to develop an anticancer cocktail to treat cancer even without using the original EVs.